Broomfield-based Accera Inc. has reached 75 percent enrollment in one of its late-stage clinical trials for an investigational new drug that .
officials said Tuesday that they hit the 75 percent mark for the NOURISH AD Phase 3 clinical study of investigational drug AC-1204. The trial, one of two Phase 3 clinical studies planned for the potential treatment, will examine the effects of AC-1204 on memory and cognition over a period of 26 weeks.
The study has a planned enrollment of 480 patients.
“The NOURISH AD trial is progressing well, and we expect to complete enrollment mid-next year,” said Charles Stacey, newly appointed Accera president and CEO, in a statement. “The repeated failure of pipeline drugs for Alzheimer’s disease emphasizes the need to explore new mechanisms in order to identify new options for patients. The NOURISH AD study represents a differentiated approach to tackling this disease.”
Accera appointed Stacey to advance AC-1204, developed to boost ketone levels in the brain to help serve as an alternative fuel to glucose.
If AC-1204 is successful in its clinical trials and regulatory reviews, FDA approval could come after 2020 or 2021.
Alicia Wallace: 303-954-1939, awallace@denverpost.com or twitter.com/aliciawallace
